Zevenbergen Capital Investments LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 24.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,724 shares of the company's stock after selling 3,500 shares during the period. Zevenbergen Capital Investments LLC's holdings in Johnson & Johnson were worth $1,551,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in JNJ. Raymond James Financial Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,339,878,000. Janus Henderson Group PLC grew its position in shares of Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after buying an additional 2,356,359 shares during the period. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the period. Finally, Amundi boosted its stake in Johnson & Johnson by 16.2% during the 4th quarter. Amundi now owns 11,930,183 shares of the company's stock worth $1,698,984,000 after acquiring an additional 1,660,458 shares during the last quarter. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Performance
JNJ traded down $2.15 during trading on Tuesday, hitting $161.14. The stock had a trading volume of 7,455,254 shares, compared to its average volume of 7,088,162. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $388.32 billion, a price-to-earnings ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a 50 day moving average price of $157.37 and a 200-day moving average price of $156.16. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $171.33.
Read Our Latest Stock Report on Johnson & Johnson
Insider Buying and Selling at Johnson & Johnson
In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
